# Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

> **NCT00988429** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 653 (actual)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** 800 mg QD Eslicarbazepine acetate
- **DRUG:** 1200 mg QD Eslicarbazepine acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00988429
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-02
- **Primary completion:** 2012-01-12
- **Final completion:** 2012-01-12
- **Target enrollment:** 653 (ACTUAL)
- **Last updated:** 2021-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988429, "Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00988429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*